1. Home
  2. LZM vs CAPR Comparison

LZM vs CAPR Comparison

Compare LZM & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LZM
  • CAPR
  • Stock Information
  • Founded
  • LZM 2021
  • CAPR 2005
  • Country
  • LZM Isle of Man
  • CAPR United States
  • Employees
  • LZM N/A
  • CAPR N/A
  • Industry
  • LZM Metal Mining
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LZM Basic Materials
  • CAPR Health Care
  • Exchange
  • LZM Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • LZM 528.1M
  • CAPR 578.4M
  • IPO Year
  • LZM N/A
  • CAPR N/A
  • Fundamental
  • Price
  • LZM $6.57
  • CAPR $14.06
  • Analyst Decision
  • LZM Strong Buy
  • CAPR Strong Buy
  • Analyst Count
  • LZM 2
  • CAPR 7
  • Target Price
  • LZM $12.50
  • CAPR $39.29
  • AVG Volume (30 Days)
  • LZM 110.7K
  • CAPR 1.1M
  • Earning Date
  • LZM 01-28-2025
  • CAPR 02-27-2025
  • Dividend Yield
  • LZM N/A
  • CAPR N/A
  • EPS Growth
  • LZM N/A
  • CAPR N/A
  • EPS
  • LZM N/A
  • CAPR N/A
  • Revenue
  • LZM $1,020,728.00
  • CAPR $23,228,045.00
  • Revenue This Year
  • LZM N/A
  • CAPR N/A
  • Revenue Next Year
  • LZM $890.00
  • CAPR $74.85
  • P/E Ratio
  • LZM N/A
  • CAPR N/A
  • Revenue Growth
  • LZM N/A
  • CAPR 65.33
  • 52 Week Low
  • LZM $4.52
  • CAPR $3.52
  • 52 Week High
  • LZM $9.51
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • LZM 42.82
  • CAPR 48.54
  • Support Level
  • LZM $6.38
  • CAPR $12.31
  • Resistance Level
  • LZM $6.90
  • CAPR $16.17
  • Average True Range (ATR)
  • LZM 0.25
  • CAPR 0.82
  • MACD
  • LZM -0.04
  • CAPR 0.11
  • Stochastic Oscillator
  • LZM 22.29
  • CAPR 45.34

About LZM Lifezone Metals Limited

Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining and to become an emerging supplier of responsibly sourced, lower-carbon and lower-sulfur dioxide emission metals to the battery, EV, and hydrogen markets modern pre-development exploration-stage metals company. Its business comprises two segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania and Intellectual property licensing comprises patents residing with and managed by the subsidiary.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

Share on Social Networks: